These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23842012)

  • 1. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?
    Nielsen J; Correll CU; Manu P; Kane JM
    J Clin Psychiatry; 2013 Jun; 74(6):603-13; quiz 613. PubMed ID: 23842012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases.
    Manu P; Lapitskaya Y; Shaikh A; Nielsen J
    Am J Ther; 2018; 25(2):e218-e223. PubMed ID: 29505490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.
    Manu P; Sarpal D; Muir O; Kane JM; Correll CU
    Schizophr Res; 2012 Feb; 134(2-3):180-6. PubMed ID: 22113154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognition and management of clozapine adverse effects: A systematic review and qualitative synthesis.
    Gurrera RJ; Gearin PF; Love J; Li KJ; Xu A; Donaghey FH; Gerace MR
    Acta Psychiatr Scand; 2022 May; 145(5):423-441. PubMed ID: 35178700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and clinical management of clozapine-induced fever.
    Lowe CM; Grube RR; Scates AC
    Ann Pharmacother; 2007 Oct; 41(10):1700-4. PubMed ID: 17785616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy.
    Cohen D; Bogers JP; van Dijk D; Bakker B; Schulte PF
    J Clin Psychiatry; 2012 Oct; 73(10):1307-12. PubMed ID: 23140648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical determinants of fever in clozapine users and implications for treatment management: A narrative review.
    Verdoux H; Quiles C; de Leon J
    Schizophr Res; 2019 Sep; 211():1-9. PubMed ID: 31378552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service.
    Reinders J; Parsonage W; Lange D; Potter JM; Plever S
    Aust N Z J Psychiatry; 2004; 38(11-12):915-22. PubMed ID: 15555025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clozapine and Fever: A Case of Continued Therapy With Clozapine.
    Bruno V; Valiente-Gómez A; Alcoverro O
    Clin Neuropharmacol; 2015; 38(4):151-3. PubMed ID: 26166236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review and management of clozapine side effects.
    Miller DD
    J Clin Psychiatry; 2000; 61 Suppl 8():14-7; discussion 18-9. PubMed ID: 10811238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review.
    Corbeil O; Béchard L; Fournier É; Plante M; Thivierge MA; Lafrenière CÉ; Huot-Lavoie M; Brodeur S; Essiambre AM; Roy MA; Demers MF
    J Psychopharmacol; 2023 Apr; 37(4):370-377. PubMed ID: 36794520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities.
    Whiskey E; Taylor D
    CNS Drugs; 2007; 21(1):25-35. PubMed ID: 17190527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood dyscrasias in clozapine-treated patients in Italy.
    Lambertenghi Deliliers G
    Haematologica; 2000 Mar; 85(3):233-7. PubMed ID: 10702809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety aspects during treatment with clozapine. : Monitoring and rechallenge - a narrative review].
    Berger SJ; Hofer A
    Neuropsychiatr; 2023 Sep; 37(3):130-135. PubMed ID: 37389803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guide to the Management of Clozapine-Related Tolerability and Safety Concerns.
    Citrome L; McEvoy JP; Saklad SR
    Clin Schizophr Relat Psychoses; 2016; 10(3):163-177. PubMed ID: 27732102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of clozapine safety.
    Fitzsimons J; Berk M; Lambert T; Bourin M; Dodd S
    Expert Opin Drug Saf; 2005 Jul; 4(4):731-44. PubMed ID: 16011451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients.
    Davis MC; Fuller MA; Strauss ME; Konicki PE; Jaskiw GE
    Acta Psychiatr Scand; 2014 Jul; 130(1):30-9. PubMed ID: 24299466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic malignant syndrome associated with long-term clozapine treatment: report of a case and results of a clozapine rechallenge.
    Huang TL
    Chang Gung Med J; 2001 Aug; 24(8):522-5. PubMed ID: 11601195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clozapine safety, 40 years later.
    Raja M; Raja S
    Curr Drug Saf; 2014; 9(3):163-95. PubMed ID: 24809463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse cardiac effects associated with clozapine.
    Merrill DB; Dec GW; Goff DC
    J Clin Psychopharmacol; 2005 Feb; 25(1):32-41. PubMed ID: 15643098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.